Skip to main content
Erschienen in: Journal of Radiation Oncology 1/2016

01.03.2016 | Original Research

Re-implantation following suboptimal dosimetry in low-dose-rate prostate brachytherapy: technique for outpatient source insertion using local anesthesia

verfasst von: Rachit Kumar, Yi Le, Theodore Deweese, Daniel Y. Song

Erschienen in: Journal of Radiation Oncology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

The objective of this study is to describe our method and results for improvement of suboptimal initial post-implant dosimetry using targeted seed placement under local anesthesia within a clinic setting.

Methods

Re-implantation was performed in an outpatient clinic using local anesthesia with transrectal ultrasound (TRUS) and template-guided insertion of additional seeds in a shielded suite without general anesthesia. Patient reported discomfort is minimal, and time to complete the procedure is 30 min or less. D90 and V100 were used to measure implantation quality in both the initial and re-implantation setting.

Results

Ten patients were treated from October 2010 to December 2012 with additional Pd-103 seeds to improve initial post-implant dosimetry. A median of 73 seeds were placed initially (range 55–113), and a median of 3 additional seeds added later (range 2–6). Re-implantation was performed a median of 31 days after initial implantation (range 12–70). Median initial D90 was 100.2 % and initial V100 was 90.1 %. The median increase in D90 was 25.7 % (range 10.2–44.4 %), and the corresponding V100 increased by a median of 6.6 % (range 3.3–14.2 %). Median urethral D30 increased by 4.1 % (range 0.9–25 %) and rectal V100 increased by a median of 0.01 cm3 (range 0–0.75 cm3). A potential operating room cost reduction of $4000–$7000 and additional savings from general anesthesia fees is possible.

Conclusions

Re-implantation under local anesthesia for LDR prostate brachytherapy improves suboptimal dosimetry and avoids the risk and cost of OR/anesthesia time.
Literatur
1.
Zurück zum Zitat Grimm P, Billiet I, Bostwick D et al (2012) Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 109:22–29CrossRefPubMed Grimm P, Billiet I, Bostwick D et al (2012) Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 109:22–29CrossRefPubMed
2.
Zurück zum Zitat Crook JM, Gomez-Iturriaga A, Wallace K et al (2011) Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. J Clin Oncol 29:362–368CrossRefPubMed Crook JM, Gomez-Iturriaga A, Wallace K et al (2011) Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. J Clin Oncol 29:362–368CrossRefPubMed
3.
Zurück zum Zitat Herstein A, Wallner K, Merrick G et al (2005) I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial. Cancer J 11:385–389CrossRefPubMed Herstein A, Wallner K, Merrick G et al (2005) I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial. Cancer J 11:385–389CrossRefPubMed
4.
Zurück zum Zitat Potters L, Cao Y, Calugaru E et al (2001) A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 50:605–614CrossRefPubMed Potters L, Cao Y, Calugaru E et al (2001) A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 50:605–614CrossRefPubMed
5.
Zurück zum Zitat Nag S, Bice W, DeWyngaert K et al (2000) The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 46:221–230CrossRefPubMed Nag S, Bice W, DeWyngaert K et al (2000) The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 46:221–230CrossRefPubMed
6.
Zurück zum Zitat Hughes L, Waterman FM, Dicker AP (2005) Salvage of suboptimal prostate seed implantation: Reimplantation of underdosed region of prostate base. Brachytherapy 4:163–170CrossRefPubMed Hughes L, Waterman FM, Dicker AP (2005) Salvage of suboptimal prostate seed implantation: Reimplantation of underdosed region of prostate base. Brachytherapy 4:163–170CrossRefPubMed
7.
Zurück zum Zitat Keyes M, Pickles T, Agranovich A et al (2004) 125I reimplantation in patients with poor initial dosimetry after prostate brachytherapy. Int J Radiat Oncol Biol Phys 60:40–50CrossRefPubMed Keyes M, Pickles T, Agranovich A et al (2004) 125I reimplantation in patients with poor initial dosimetry after prostate brachytherapy. Int J Radiat Oncol Biol Phys 60:40–50CrossRefPubMed
8.
Zurück zum Zitat Zaider M (2009) Dosimetric guidance on using brachytherapy (low-dose-rate or high-dose-rate) to offset a flawed permanent prostate implant. Brachytherapy 8:40–44CrossRefPubMed Zaider M (2009) Dosimetric guidance on using brachytherapy (low-dose-rate or high-dose-rate) to offset a flawed permanent prostate implant. Brachytherapy 8:40–44CrossRefPubMed
9.
Zurück zum Zitat Shah C, Lanni TB Jr, Ghilezan MI et al (2012) Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. Brachytherapy 11:441–445CrossRefPubMed Shah C, Lanni TB Jr, Ghilezan MI et al (2012) Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. Brachytherapy 11:441–445CrossRefPubMed
10.
Zurück zum Zitat Eldefrawy A, Katkoori D, Abramowitz M et al (2013) Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison. Urol Oncol 31(5):576–580CrossRefPubMed Eldefrawy A, Katkoori D, Abramowitz M et al (2013) Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison. Urol Oncol 31(5):576–580CrossRefPubMed
11.
Zurück zum Zitat Roessler B, Six LM, Gustorff B (2008) Anaesthesia for brachytherapy. Curr Opin Anaesthesiol 21:514–518CrossRefPubMed Roessler B, Six LM, Gustorff B (2008) Anaesthesia for brachytherapy. Curr Opin Anaesthesiol 21:514–518CrossRefPubMed
12.
Zurück zum Zitat Wojcieszek E, Rembielak A, Bialas B et al (2010) Anaesthesia for radiation therapy—Gliwice experience. Neoplasma 57:155–160CrossRefPubMed Wojcieszek E, Rembielak A, Bialas B et al (2010) Anaesthesia for radiation therapy—Gliwice experience. Neoplasma 57:155–160CrossRefPubMed
13.
Zurück zum Zitat Yue N, Dicker AP, Nath R et al (1999) The impact of edema on planning 125I and 103Pd prostate implants. Med Phys 26:763–767CrossRefPubMed Yue N, Dicker AP, Nath R et al (1999) The impact of edema on planning 125I and 103Pd prostate implants. Med Phys 26:763–767CrossRefPubMed
14.
Zurück zum Zitat Zelefsky MJ, Yamada Y, Cohen GN et al (2007) Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications. Radiother Oncol 84:185–189CrossRefPubMed Zelefsky MJ, Yamada Y, Cohen GN et al (2007) Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications. Radiother Oncol 84:185–189CrossRefPubMed
15.
Zurück zum Zitat Stone NN, Stone MM, Rosenstein BS et al (2011) Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol 185:495–500CrossRefPubMed Stone NN, Stone MM, Rosenstein BS et al (2011) Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol 185:495–500CrossRefPubMed
16.
Zurück zum Zitat Wallner K (2002) Prostate brachytherapy under local anesthesia; lessons from the first 600 patients. Brachytherapy 1(3):145–148CrossRefPubMed Wallner K (2002) Prostate brachytherapy under local anesthesia; lessons from the first 600 patients. Brachytherapy 1(3):145–148CrossRefPubMed
17.
Zurück zum Zitat Su Y, Davis BJ, Furutani KM et al (2007) Seed localization and TRUS fluoroscopy fusion for intraoperative prostate brachytherapy dosimetry. Comput Aided Surg 12:25–34CrossRefPubMed Su Y, Davis BJ, Furutani KM et al (2007) Seed localization and TRUS fluoroscopy fusion for intraoperative prostate brachytherapy dosimetry. Comput Aided Surg 12:25–34CrossRefPubMed
18.
Zurück zum Zitat Song DY, Jain AK, Zhang Z et al (2011) Dynamic intraoperative dosimetry for prostate brachytherapy using a nonisocentric C-arm. Brachytherapy 10(2):98–106CrossRefPubMed Song DY, Jain AK, Zhang Z et al (2011) Dynamic intraoperative dosimetry for prostate brachytherapy using a nonisocentric C-arm. Brachytherapy 10(2):98–106CrossRefPubMed
Metadaten
Titel
Re-implantation following suboptimal dosimetry in low-dose-rate prostate brachytherapy: technique for outpatient source insertion using local anesthesia
verfasst von
Rachit Kumar
Yi Le
Theodore Deweese
Daniel Y. Song
Publikationsdatum
01.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Radiation Oncology / Ausgabe 1/2016
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-015-0198-3

Weitere Artikel der Ausgabe 1/2016

Journal of Radiation Oncology 1/2016 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.